Priveterra Acquisition Corp.

Status: Deal Closed
U=S+W/3 W=S@11.5
IPO Proceeds, $M $276.00M
IPO Date Feb 9, 2021
CEO Robert Palmisano
Left Lead Wells Fargo
IPO Cash in Trust 100.0%
SPAC Tenor 24 + 6
IPO Sector Healthcare

Medical technology

IPO Geography Global
Target Company AEON Biopharma
Deal Announced Dec 13, 2022
Deal Size, $M $220.80M
Deal Sector Healthcare
Deal Geography US/Canada
SEC Filings www.sec.gov
Approval Vote Jul 3, 2023
Amendment Vote Feb 10, 2023
Closing Date Jul 21, 2023
Formerly PMGM AEON AEON/W

Sign up for Free Trial

No credit card required

Sign in for more on Priveterra Acquisition Corp.:

  • Structure and cap table
  • 7 directors & officers
  • 44 filings and events
  • 3 underwriters
  • 3 deal advisors
  • 2 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Robert Palmisano 76 Chairman and Chief Executive Officer
Vikram Malik 58 President and Director
Oleg Grodnensky 43 Chief Operating Officer and Chief Financial Officer
David Meredith 52 Chief Legal Officer and Secretary
Lance A. Berry 48 Director
James A. Lightman 62 Director
Julie B. Andrews 49 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Wells Fargo Joint BR 11,520,000 units
Guggenheim Securities Joint BR 9,360,000
Odeon Capital Group 3,120,000
24,000,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.50 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 44 filings.

Shareholders

Sign in to view shareholders 13F filing data.